Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SYK regulates mTOR signaling in AML.
Carnevale J, Ross L, Puissant A, Banerji V, Stone RM, DeAngelo DJ, Ross KN, Stegmaier K. Carnevale J, et al. Among authors: puissant a. Leukemia. 2013 Nov;27(11):2118-28. doi: 10.1038/leu.2013.89. Epub 2013 Mar 28. Leukemia. 2013. PMID: 23535559 Free PMC article.
SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, Hemann MT, Stegmaier K. Puissant A, et al. Cancer Cell. 2014 Feb 10;25(2):226-42. doi: 10.1016/j.ccr.2014.01.022. Cancer Cell. 2014. PMID: 24525236 Free PMC article.
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU. Lindblad O, et al. Among authors: puissant a. Oncogene. 2016 Sep 29;35(39):5119-31. doi: 10.1038/onc.2016.41. Epub 2016 Mar 21. Oncogene. 2016. PMID: 26999641 Free PMC article.
Targeting MTHFD2 in acute myeloid leukemia.
Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K. Pikman Y, et al. Among authors: puissant a. J Exp Med. 2016 Jun 27;213(7):1285-306. doi: 10.1084/jem.20151574. Epub 2016 Jun 20. J Exp Med. 2016. PMID: 27325891 Free PMC article.
Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor.
Roux B, Vaganay C, Vargas JD, Alexe G, Benaksas C, Pardieu B, Fenouille N, Ellegast JM, Malolepsza E, Ling F, Sodaro G, Ross L, Pikman Y, Conway AS, Tang Y, Wu T, Anderson DJ, Le Moigne R, Zhou HJ, Luciano F, Hartigan CR, Galinsky I, DeAngelo DJ, Stone RM, Auberger P, Schenone M, Carr SA, Guirouilh-Barbat J, Lopez B, Khaled M, Lage K, Hermine O, Hemann MT, Puissant A, Stegmaier K, Benajiba L. Roux B, et al. Among authors: puissant a. Sci Transl Med. 2021 Mar 31;13(587):eabg1168. doi: 10.1126/scitranslmed.abg1168. Sci Transl Med. 2021. PMID: 33790022 Free PMC article.
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.
Pardieu B, Pasanisi J, Ling F, Dal Bello R, Penneroux J, Su A, Joudinaud R, Chat L, Wu HC, Duchmann M, Sodaro G, Chauvel C, Castelli FA, Vasseur L, Pacchiardi K, Belloucif Y, Laiguillon MC, Meduri E, Vaganay C, Alexe G, Berrou J, Benaksas C, Forget A, Braun T, Gardin C, Raffoux E, Clappier E, Adès L, de Thé H, Fenaille F, Huntly BJ, Stegmaier K, Dombret H, Fenouille N, Lobry C, Puissant A, Itzykson R. Pardieu B, et al. Among authors: puissant a. Leukemia. 2022 Jun;36(6):1585-1595. doi: 10.1038/s41375-022-01573-6. Epub 2022 Apr 26. Leukemia. 2022. PMID: 35474100
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K. Fenouille N, et al. Among authors: puissant a. Nat Med. 2017 Mar;23(3):301-313. doi: 10.1038/nm.4283. Epub 2017 Feb 13. Nat Med. 2017. PMID: 28191887 Free PMC article.
Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, Ross L, Puissant A, Alexe G, Conway A, Back M, Pikman Y, Galinsky I, DeAngelo DJ, Stone RM, Kaya T, Shi X, Robers MB, Machleidt T, Wilkinson J, Hermine O, Kung A, Stein AJ, Lakshminarasimhan D, Hemann MT, Scolnick E, Zhang YL, Pan JQ, Stegmaier K, Holson EB. Wagner FF, et al. Among authors: puissant a. Sci Transl Med. 2018 Mar 7;10(431):eaam8460. doi: 10.1126/scitranslmed.aam8460. Sci Transl Med. 2018. PMID: 29515000 Free PMC article.
Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.
Benajiba L, Alexe G, Su A, Raffoux E, Soulier J, Hemann MT, Hermine O, Itzykson R, Stegmaier K, Puissant A. Benajiba L, et al. Among authors: puissant a. Leukemia. 2019 Mar;33(3):800-804. doi: 10.1038/s41375-018-0291-x. Epub 2018 Nov 2. Leukemia. 2019. PMID: 30390009 Free PMC article. No abstract available.
300 results